ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ:HGSI) today announced that its senior management will discuss BENLYSTA and the Phase 3 BLISS-52 trial results during an Analyst & Investor Meeting the Company will host at the 2009 American College of Rheumatology Annual Scientific Meeting. The HGSI Analyst & Investor meeting will begin at approximately 6:30 PM Eastern on Tuesday, October 20, 2009, and will be accessible by webcast at www.hgsi.com.
